Loading...
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.
Gilham, David E Debets, R Pule, M Hawkins, Robert E Abken, Hinrich
Gilham, David E
Debets, R
Pule, M
Hawkins, Robert E
Abken, Hinrich
Citations
Altmetric:
Abstract
Recent reports on the impressive efficacy of adoptively transferred T cells to challenge cancer in early phase clinical trials have significantly raised the profile of T cell therapy. Concomitantly, general expectations are also raised by these reports, with the natural aspiration to deliver this therapy over a wide range of tumor indications. Chimeric antigen receptors (CARs) endow T cell populations with defined antigen specificities that function independently of the natural T cell receptor and permit targeting of T cells towards virtually any tumor. Here, we review the current clinical application of CAR-T cells and relate clinical efficacy and safety of CAR-T cell trials to parameters considered critical for CAR engineering, classified as the three T's of CAR-T cell manipulation.
Description
Date
2012-07
Publisher
Collections
Keywords
Type
Article
Citation
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. 2012, 18 (7):377-84 Trends Mol Med